DGX
Quest Diagnostics
September 15, 2026 · intraday
- Rarity
- 1.66
- Peak move
- +4.44%
- Float cap
- $26.0B
Quest Diagnostics provides diagnostic information services through laboratory testing, offering insights from clinical lab results to help physicians, hospitals, patients, consumers, health plans, government agencies, employers, and other healthcare organizations improve health outcomes. It operates patient service centers, laboratory facilities, and consumer-initiated testing through QuestHealth.com. The company serves about half of U.S. physicians and hospitals annually.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
7 events · 0 from SEC or newswire · 0 timed with the move- Key event
guidance_changeAt Morgan Stanley's 24th Annual Global Healthcare Conference on Sept 14, 2026, Quest Diagnostics CFO Sam Samad said FY2026 revenue growth guidance is 8.3%-9.2% (revenue $11.95B-$12.05B), with operating margin expansion still expected in 2026 and 75-150 bps of margin expansion expected over 2025-2027, plus updated long-term targets due at a March 2027 investor day.
- Key event
executive_remarkQuest Diagnostics management said at the Morgan Stanley healthcare conference on Sept 14, 2026 that the industry-wide PAMA lab-test pricing impact is expected capped at about $100 million, with Quest expecting to offset less than half its own exposure, clarity on CMS data collection by early October 2026, and noting the RESULTS Act has 100+ bipartisan supporters.
investor_dayQuest Diagnostics said at the Morgan Stanley 24th Annual Global Healthcare Conference on Sept 14, 2026 that it will provide updated long-term growth and margin targets at an investor day in March 2027, while reiterating 75-150 bps of margin expansion over 2025-2027.
regulatory_approvalQuest Diagnostics said its Haystack MRD cancer-monitoring test received New York State approval in Q2 2026, allowing commercial rollout to all 50 states, with the test integrated with Flatiron Health's Onco EMR and a MolDX technical assessment pending for Medicare Advantage coverage.
major_contractQuest Diagnostics described new partnerships with Corewell Health in Michigan and Fresenius Medical Care for clinical testing in its dialysis business, contributing 9% of Q2 volume, with the Corewell relationship expected to convert to a Michigan lab joint venture in early 2027.
executive_remarkQuest Diagnostics CFO Sam Samad said at the Morgan Stanley 24th Annual Global Healthcare Conference on Sept 14, 2026 that Q2 organic volume grew ~4% and revenue per requisition rose 2.9% excluding new partnerships, while flagging slower H2 growth from health-exchange disenrollments and October 2026 partnership lapping.
- Key event
product_launchQuest Diagnostics said its Apple partnership will offer an 8-10 test panel with 50 biomarkers through the Apple Health app using its network of 2,000 patient service centers with no patient-acquisition cost to Quest; consumer business is ~$300M annually growing ~30%, with management expecting growth above 20% annually over the next three to five years.